Article
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Science translational medicine - 29 Apr 2020
Sheahan Timothy P, Sims Amy C, Zhou Shuntai, Graham Rachel L, Pruijssers Andrea J, Agostini Maria L, Leist Sarah R, Schäfer Alexandra, Dinnon Kenneth H, Stevens Laura J, Chappell James D, Lu Xiaotao, Hughes Tia M, George Amelia S, Hill Collin S, Montgomery Stephanie A, Brown Ariane J, Bluemling Gregory R, Natchus Michael G, Saindane Manohar, Kolykhalov Alexander A, Painter George, Harcourt Jennifer, Tamin Azaibi, Thornburg Natalie J, Swanstrom Ronald, Denison Mark R, Baric Ralph S
Abstract excerpt
Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative agent of COVID-19. Here, we show that the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) has broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c bat-CoVs, as well as increased...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
